Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 12/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9986469 | 1.00 | DPP4 (0.45) | DPP4NPC1RAB9AHDAC3NCOR2 | |
| SCHEMBL6690036 | 0.88 | CYP3A4 (0.41) | DPP4NPC1RAB9AHDAC3NCOR2 | |
| SCHEMBL11911567 | 0.83 | NPC1 (0.53) | NPC1RAB9AHDAC3NCOR2 | |
| SCHEMBL9987026 | 0.81 | DPP4 (0.41) | DPP4NPC1RAB9AHDAC3NCOR2 | |
| SCHEMBL9986355 | 0.81 | DPP4 (0.41) | DPP4NPC1RAB9AHDAC3NCOR2 | |
| SCHEMBL14550107 | 0.81 | DPP4 (0.50) | DPP4DPP7DPP8DPP9CYP3A4 | |
| SCHEMBL3992005 | 0.81 | DPP4 (0.47) | DPP4DPP7DPP8DPP9CYP3A4 | |
| SCHEMBL11911576 | 0.79 | NPC1 (0.51) | NPC1RAB9AHDAC3NCOR2 | |
| SCHEMBL9985996 | 0.78 | DPP4 (0.48) | DPP4DPP7DPP8DPP9CYP3A4 | |
| SCHEMBL9985994 | 0.78 | DPP4 (0.48) | DPP4DPP7DPP8DPP9CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023175492-A1 | NOVEL INTERMEDIATES AND ITS USE IN MANUFACTURING OF SITAGLIPTIN | HIKAL LIMITED (IN) | 2023-09-21 | — | — | WO | disclosed |
| US-10450315-B2 | Process for the preparation of dipeptidyl peptidase-4 (DPP-4) enzyme inhibitor | LEE PHARMA LIMITED (IN) | 2019-10-22 | — | — | US | disclosed |
| US-20180265513-A1 | NOVEL PROCESS FOR THE PREPARATION OF DIPEPTIDYL PEPTIDASE-4 (DPP-4) ENZYME INHIBITOR | LEE PHARMA LIMITED (IN) | 2018-09-20 | — | — | US | disclosed |
| US-20180086765-A1 | NOVEL INTERMEDIATES FOR PREPARING DPP-IV INHIBITORS, PREPARING METHOD THEREOF AND PREPARING METHOD OF DPP-IV INHIBITORS USING THE SAME | KYUNG DONG PHARM. CO., LTD. (KR) | 2018-03-29 | — | — | US | disclosed |
| US-20180086765-A1 | NOVEL INTERMEDIATES FOR PREPARING DPP-IV INHIBITORS, PREPARING METHOD THEREOF AND PREPARING METHOD OF DPP-IV INHIBITORS USING THE SAME | KYUNG DONG PHARM. CO., LTD. (KR) | 2018-03-29 | — | — | US | disclosed |
| EP-3242879-A1 | NOVEL PROCESS FOR THE PREPARATION OF DIPEPTIDYL PEPTIDASE-4 (DPP-4) ENZYME INHIBITOR | Lee Pharma Ltd. (IN) | 2017-11-15 | — | — | EP | disclosed |
| EP-2861598-B1 | NEW SYNTHETIC ROUTE FOR THE PREPARATION OF ß-AMINOBUTYRYL SUBSTITUTED 5,6,7,8-TETRAHYDRO[1,4]DIAZOLO[4,3-a]PYRAZIN-7-YL COMPOUNDS | LEK PHARMACEUTICALS (SI) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016110750-A1 | NOVEL PROCESS FOR THE PREPARATION OF DIPEPTIDYL PEPTIDASE-4 (DPP-4) ENZYME INHIBITOR | LEE PHARMA LIMITED (IN) | 2016-07-14 | — | — | WO | disclosed |
| WO-2016110750-A1 | NOVEL PROCESS FOR THE PREPARATION OF DIPEPTIDYL PEPTIDASE-4 (DPP-4) ENZYME INHIBITOR | LEE PHARMA LIMITED (IN) | 2016-07-14 | — | — | WO | disclosed |
| US-9388188-B2 | Synthetic route for the preparation of β-aminobutyryl substituted 5,6,7,8-tetrahydro[1,4]diazolo[4,3-alpha ]pyrazin-7-yl compounds | LEK PHARMACEUTICALS D.D. (SI) | 2016-07-12 | — | — | US | disclosed |
| EP-2415753-A2 | IMPROVED METHOD FOR PREPARING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE | Dong-A Pharmaceutical Co., Ltd. (KR) | 2012-02-08 | — | — | EP | disclosed |
| US-20120016126-A1 | METHOD FOR MANUFACTURING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE | DONG-A PHARMACEUTICAL. CO., LTD (KR) | 2012-01-19 | — | — | US | disclosed |
| US-20120016126-A1 | METHOD FOR MANUFACTURING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE | DONG-A PHARMACEUTICAL. CO., LTD (KR) | 2012-01-19 | — | — | US | disclosed |
| US-20120016125-A1 | METHOD FOR PREPARING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE | DONG-A PHARMACEUTICAL. CO., LTD (KR) | 2012-01-19 | — | — | US | disclosed |
| US-20120016125-A1 | METHOD FOR PREPARING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE | DONG-A PHARMACEUTICAL. CO., LTD (KR) | 2012-01-19 | — | — | US | disclosed |
| EP-2397141-A1 | Process for the synthesis of beta-amino acids and derivatives thereof | LEK Pharmaceuticals d.d. (SI) | 2011-12-21 | — | — | EP | disclosed |
| WO-2011049344-A2 | METHOD OF PREPARING SITAGLIPTIN AND INTERMEDIATES USED THEREIN | HANMI HOLDINGS CO., LTD. (KR) | 2011-04-28 | — | — | WO | disclosed |
| WO-2011040717-A2 | METHOD FOR PREPARING INTERMEDIATE OF SITAGLIPTIN USING CHIRAL OXIRANE | HANMI HOLDINGS CO., LTD. (KR) | 2011-04-07 | — | — | WO | disclosed |
| WO-2010114291-A2 | IMPROVED METHOD FOR PREPARING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE | 동아제약 주식회사 (KR) | 2010-10-07 | — | — | WO | disclosed |
| WO-2010114292-A2 | IMPROVED METHOD FOR MANUFACTURING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE | 동아제약 주식회사 (KR) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120016126-A1 | METHOD FOR MANUFACTURING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE | DPP4, DPP3, DPP7 | DPP4 1/4885NPC1 1422/4885RAB9A 3993/4885 |
| US-20180086765-A1 | NOVEL INTERMEDIATES FOR PREPARING DPP-IV INHIBITORS, PREPARING METHOD THEREOF AND PREPARING METHOD OF DPP-IV INHIBITORS USING THE SAME | DPP4, DPP7, DPP9 | DPP4 1/4885NPC1 1507/4885RAB9A 3180/4885 |
| US-20120016125-A1 | METHOD FOR PREPARING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE | DPP4, DPP3, DPP7 | DPP4 1/4885NPC1 997/4885RAB9A 3651/4885 |
| US-20180265513-A1 | NOVEL PROCESS FOR THE PREPARATION OF DIPEPTIDYL PEPTIDASE-4 (DPP-4) ENZYME INHIBITOR | DPP4, DPP7, DPP9 | DPP4 1/4885NPC1 991/4885RAB9A 2823/4885 |
| US-10450315-B2 | Process for the preparation of dipeptidyl peptidase-4 (DPP-4) enzyme inhibitor | DPP4, DPP7, DPP3 | DPP4 1/4885NPC1 977/4885RAB9A 3207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.